[go: up one dir, main page]

SG11201805263TA - Compositions and methods for detecting and treating esophageal cancer - Google Patents

Compositions and methods for detecting and treating esophageal cancer

Info

Publication number
SG11201805263TA
SG11201805263TA SG11201805263TA SG11201805263TA SG11201805263TA SG 11201805263T A SG11201805263T A SG 11201805263TA SG 11201805263T A SG11201805263T A SG 11201805263TA SG 11201805263T A SG11201805263T A SG 11201805263TA SG 11201805263T A SG11201805263T A SG 11201805263TA
Authority
SG
Singapore
Prior art keywords
international
methods
esophageal cancer
compositions
rule
Prior art date
Application number
SG11201805263TA
Inventor
Alexandre Prieur
Original Assignee
Progastrine Et Cancers S A R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progastrine Et Cancers S A R L filed Critical Progastrine Et Cancers S A R L
Publication of SG11201805263TA publication Critical patent/SG11201805263TA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 6 July 2017 (06.07.2017) WIPOIPCT (10) International Publication Number WO 2017/114976 A1 (51) International Patent Classification: G01N33/574 (2006.01) C07K16/26 (2006.01) A61K39/395 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/EP2017/050037 2 January 2017 (02.01.2017) English (30) Priority Data: 15307189.9 31 December 2015 (31.12.2015) 16305139.4 5 February 2016 (05.02.2016) English EP EP (71) Applicant: PROGASTRINE ET CANCERS S.A R.L. [LU/LU]; 11, Cote d'Eich, L-1450 Luxembourg (LU). (72) Inventor: PRIEUR, Alexandre; 24 rue de la Cavalerie, 34000 Montpellier (FR). (74) Agent: REGIMBEAU; 20, rue de Chazelles, 75847 Paris Cedex 17 (FR). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) V© l> o\ •t o CJ (54) Title: COMPOSITIONS AND METHODS FOR DETECTING AND TREATING ESOPHAGEAL CANCER (57) : The present invention relates to methods for the in vitro diagnosis of esophageal cancer, and to compositions and methods for the prevention or the treatment of esophageal cancer, wherein said compositions comprise an antibody binding to pro - gastrin and said methods comprise the use of an antibody binding to progastrin.
SG11201805263TA 2015-12-31 2017-01-02 Compositions and methods for detecting and treating esophageal cancer SG11201805263TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15307189 2015-12-31
EP16305139 2016-02-05
PCT/EP2017/050037 WO2017114976A1 (en) 2015-12-31 2017-01-02 Compositions and methods for detecting and treating esophageal cancer

Publications (1)

Publication Number Publication Date
SG11201805263TA true SG11201805263TA (en) 2018-07-30

Family

ID=57821946

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805263TA SG11201805263TA (en) 2015-12-31 2017-01-02 Compositions and methods for detecting and treating esophageal cancer

Country Status (14)

Country Link
US (2) US11789021B2 (en)
EP (2) EP3848709B1 (en)
JP (2) JP7018885B2 (en)
KR (2) KR102430893B1 (en)
CN (1) CN108700589A (en)
AU (2) AU2017204686B2 (en)
BR (1) BR112018013272A2 (en)
CA (2) CA3193481A1 (en)
EA (1) EA037032B1 (en)
ES (2) ES3003287T3 (en)
PL (1) PL3397967T3 (en)
SG (1) SG11201805263TA (en)
WO (1) WO2017114976A1 (en)
ZA (1) ZA201804142B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240018264A1 (en) * 2015-12-31 2024-01-18 Progastrine Et Cancers S.À R.L. Compositions and methods for detecting and treating ovarian cancer
KR102461238B1 (en) * 2017-12-05 2022-11-01 프로가스트린 에 캔서스 에스.에이 알.엘. Combination therapy between anti-progastrin antibodies and immunotherapy to treat cancer
JP7338128B2 (en) 2017-12-08 2023-09-05 イー、シー、エス、ビオトラッカー、エス、エー、アール、エル Radiolabeled progastrin in cancer diagnosis
WO2019145537A1 (en) 2018-01-26 2019-08-01 Ecs-Progastrin Sa Combination of progastrin detection with other cancer biomarkers in cancer diagnosis
CN112368579B (en) * 2018-02-27 2024-05-03 Ecs前胃泌素股份有限公司 Progastrin as biomarker for immunotherapy
AU2019235771B2 (en) * 2018-03-13 2025-03-13 Creatv Microtech, Inc. Methods for monitoring treatment response and disease progression in subjects using circulating cells
KR102167078B1 (en) * 2019-07-19 2020-10-16 (주)파즈코리아 Transfering device for blood samples
WO2021081498A1 (en) * 2019-10-24 2021-04-29 The Johns Hopkins University Compositions and methods for detecting and treating esophageal cancer
JP7287532B2 (en) * 2020-08-04 2023-06-06 王子ホールディングス株式会社 toilet roll

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
JPH05244982A (en) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd Humanized b-b10
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DE69637481T2 (en) 1995-04-27 2009-04-09 Amgen Fremont Inc. Human antibodies to IL-8 derived from immunized Xenomae
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ES2301183T3 (en) 1996-12-03 2008-06-16 Amgen Fremont Inc. COMPLETELY HUMAN ANTIBODY THAT JOINS THE EGFR RECEIVER.
CN100387621C (en) 1997-04-14 2008-05-14 麦可麦脱股份公司 Production method and use of anti-human antigen receptor
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20030021786A1 (en) * 2001-07-09 2003-01-30 Gevas Philip C. Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
DK1794586T3 (en) 2004-09-22 2013-05-13 Cancer Advances Inc Monoclonal antibodies to progastrin
US8278421B2 (en) * 2006-03-20 2012-10-02 Xoma Techolology Ltd. Human antibodies specific for gastrin materials and methods
US7854932B2 (en) * 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
US20110085986A1 (en) * 2009-10-13 2011-04-14 Pomila Singh Diagnosis and treatment of epithelial cancers using labeled/conjugated progastrin peptides
US9217032B2 (en) * 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
US9487582B2 (en) 2010-01-08 2016-11-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for treating pancreatic cancer
US8900817B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
ES2754774T3 (en) 2010-03-24 2020-04-20 Progastrine Et Cancers S A R L Colorectal and gastrointestinal cancer prophylaxis
AU2011284908B2 (en) 2010-07-26 2015-05-21 Centre National De La Recherche Scientifique (Cnrs) Methods and compositions for liver cancer therapy
FI20145550A7 (en) * 2014-06-13 2015-12-14 Biohit Oyj Use of gastrin-17 as biomarker for atrophic gastritis with increased risk of several related sequels
WO2016066671A1 (en) 2014-10-29 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant cancers using progastrin inhibitors

Also Published As

Publication number Publication date
EP3848709C0 (en) 2024-12-04
JP7018885B2 (en) 2022-02-14
EA037032B1 (en) 2021-01-28
JP7363007B2 (en) 2023-10-18
CA3193481A1 (en) 2017-07-06
ZA201804142B (en) 2019-11-27
WO2017114976A1 (en) 2017-07-06
KR102197478B1 (en) 2021-01-04
KR20180108586A (en) 2018-10-04
JP2019505785A (en) 2019-02-28
US11789021B2 (en) 2023-10-17
EP3397967A1 (en) 2018-11-07
BR112018013272A2 (en) 2018-12-11
AU2017204686B2 (en) 2020-04-30
EP3397967B1 (en) 2020-12-30
EA201891527A1 (en) 2019-01-31
ES2861587T3 (en) 2021-10-06
CN108700589A (en) 2018-10-23
KR20210002363A (en) 2021-01-07
JP2022064969A (en) 2022-04-26
AU2020202296A1 (en) 2020-04-23
EP3848709B1 (en) 2024-12-04
AU2020202296B2 (en) 2022-06-02
AU2017204686A1 (en) 2018-07-05
ES3003287T3 (en) 2025-03-10
US20190011447A1 (en) 2019-01-10
US20240085423A1 (en) 2024-03-14
CA3009785A1 (en) 2017-07-06
KR102430893B1 (en) 2022-08-09
EP3848709A1 (en) 2021-07-14
PL3397967T3 (en) 2021-06-28

Similar Documents

Publication Publication Date Title
SG11201805263TA (en) Compositions and methods for detecting and treating esophageal cancer
SG11201805605TA (en) Compositions and methods for detecting and treating ovarian cancer
SG11201908888VA (en) Compositions and methods for treating lung cancer
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201908998XA (en) Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201900885VA (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201407534PA (en) New diazaspirocycloalkane and azaspirocycloalkane
SG11201407859YA (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
SG11201809625RA (en) 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer
SG11201407802WA (en) Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201808125RA (en) Methods for solid tumor treatment
SG11201408605UA (en) Methods for biodegradable derivatization of cellulosic surfaces
SG11201809531SA (en) BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF
SG11201803643TA (en) Virulence attenuated bacteria for treatment of malignant solid tumors
SG11201907693VA (en) Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
SG11201900021PA (en) Methods and compositions for the treatment of cancer
SG11201908602UA (en) Combination therapy for the treatment of solid and hematological cancers
SG11201907927SA (en) Binding molecules that specifically bind to tau